Cellular immune responses to four doses of percutaneous bacille Calmette-Guerin in healthy adults

被引:18
作者
Lowry, PW
Ludwig, TS
Adams, JA
Fitzpatrick, ML
Grant, SM
Andrle, GA
Offerdahl, MR
Cho, SN
Jacobs, DR
机构
[1] Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Sch Publ Hlth, Dept Med, Minneapolis, MN USA
[3] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA
[4] Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA
关键词
D O I
10.1086/515614
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To explore the hypothesis that low-dose immunization might induce preferential Th1 cell immunity, 76 adults were vaccinated with one of four doses of bacille Calmette-Guerin (BCG):The doses contained very low (1.6 X 10(5) cfu), low (3.2 x 10(6) cfu), standard (1.6 x 10(8) cfu), or high (3.2 x 10(8) cfu) levels of BCG. Delayed-type hypersensitivity responses occurred 8 weeks after vaccination in 10% of persons given very low or low doses of BCG, compared with 95% and 100% of persons given standard or high doses, respectively. Lymphoproliferative responses, which were increased only for high-dose vaccinees, peaked 2 weeks after vaccination and were directed chiefly against Mycobacterium tuberculosis-secreted proteins, particularly the antigen 85 complex. Significant increases in mycobacteria-specific interferon-gamma expression were present 16 weeks after vaccination only for persons given standard or high doses of BCG. Percutaneous BCG appears capable of inducing a temporary Th1-like immune response, but standard or higher dosages are required.
引用
收藏
页码:138 / 146
页数:9
相关论文
共 44 条
[11]   SEROLOGICAL SPECIFICITY OF PHENOLIC GLYCOLIPID-I FROM MYCOBACTERIUM-LEPRAE AND USE IN SERODIAGNOSIS OF LEPROSY [J].
CHO, SN ;
YANAGIHARA, DL ;
HUNTER, SW ;
GELBER, RH ;
BRENNAN, PJ .
INFECTION AND IMMUNITY, 1983, 41 (03) :1077-1083
[12]   BACTERIAL VACCINE VECTORS AND BACILLUS-CALMETTE-GUERIN [J].
CIRILLO, JD ;
STOVER, CK ;
BLOOM, BR ;
JACOBS, WR ;
BARLETTA, RG .
CLINICAL INFECTIOUS DISEASES, 1995, 20 (04) :1001-1009
[13]   EFFICACY OF BCG VACCINE IN THE PREVENTION OF TUBERCULOSIS - METAANALYSIS OF THE PUBLISHED LITERATURE [J].
COLDITZ, GA ;
BREWER, TF ;
BERKEY, CS ;
WILSON, ME ;
BURDICK, E ;
FINEBERG, HV ;
MOSTELLER, F .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (09) :698-702
[14]   EVIDENCE FOR GLYCOSYLATION SITES ON THE 45-KILODALTON GLYCOPROTEIN OF MYCOBACTERIUM-TUBERCULOSIS [J].
DOBOS, KM ;
SWIDEREK, K ;
KHOO, KH ;
BRENNAN, PJ ;
BELISLE, JT .
INFECTION AND IMMUNITY, 1995, 63 (08) :2846-2853
[15]  
DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213
[16]   ABSENCE OF IGM AND IGG ANTIBODY-RESPONSE TO THE 3 COMPONENTS OF THE MYCOBACTERIUM-BOVIS BCG 85 COMPLEX ANTIGEN AFTER BCG VACCINATION [J].
DROWART, A ;
SELLESLAGLS, J ;
HUYGEN, K ;
DEBRUYN, J ;
VANVOOREN, JP .
CHEST, 1993, 103 (01) :320-321
[17]  
Fine P E, 1986, Lepr Rev, V57 Suppl 2, P275
[18]  
Fine PE., 1989, REV INFECT DIS S2, V11, P353
[19]   DELAYED-TYPE HYPERSENSITIVITY, MYCOBACTERIAL VACCINES AND PROTECTIVE IMMUNITY [J].
FINE, PEM ;
STERNE, JAC ;
PONNIGHAUS, JM ;
REES, RJW .
LANCET, 1994, 344 (8932) :1245-1249
[20]  
FLESCH I, 1987, J IMMUNOL, V138, P4408